New medical devices could start undergoing review for Medicare coverage before receiving FDA marketing authorization under a proposed rule the Biden administration plans to release in the coming months.
Officials from the Centers for Medicare & Medicaid Services announced Wednesday that the proposal would establish a pathway that medical device manufacturers can enter on a voluntary basis to start getting their products reviewed earlier. The action is part of a series of efforts by the CMS and the Food and Drug Administration to better coordinate their product reviews so that patients can get quicker access to novel treatments and emerging ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.